Skip to main content
SpringerLink
Log in
Book cover

Cannabis Use Disorders pp 177–188Cite as

Cannabis Use Disorder During the Perinatal Period

  • Chapter
  • First Online:

Abstract

Cannabis use among pregnant and parenting women is increasing in the USA, alongside escalating THC potency in available cannabis products and the use of synthetic preparations. Existing information on how cannabis use during pregnancy may impact the course of pregnancy and fetal/child development is limited, and studies that evaluate birth outcomes and postnatal development of prenatally exposed children are inconsistent. However, accumulating neurodevelopmental data in animals and humans shows that pre- and postnatal cannabis exposure portends harm for the developing fetus and the child. THC crosses the placental barrier, and current evidence indicates that prenatal cannabis use, especially during critical periods of brain development, places the developing child at risk for neuropsychiatric, behavioral, and substance abuse problems. The extensive legalization of cannabis, the recent increase in marijuana use by pregnant women, the availability of cannabis with higher THC concentrations, and the introduction and escalating use of synthetic cannabinoids create an urgent need to determine the effects of the amplified fetal THC exposure. The risk of neurodevelopmental problems in THC-exposed children may be enhanced if the child is raised by a mother affected by neurobehavioral dysfunctions and associated comorbidities of an active cannabis use disorder. Identification and treatment of cannabis use and cannabis use disorder in women during the perinatal period should be a high clinical priority. Misperception of risk, inadequacy of provider knowledge and training, and scarcity of time and resources to comprehensively address the needs of cannabis-exposed mother-child dyads are common among health providers. Although more research is needed to establish the perinatal effects of maternal cannabis use, pregnant and postpartum women should be aware that perinatal cannabis use risks safety for both mother and child. This chapter provides an overview of the epidemiology of perinatal cannabis use, the neurobehavioral effects of prenatal cannabis exposure for the developing child, and the treatment strategies for the mother-child dyad affected by cannabis use.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Brown QL, Sarvet AL, Shmulewitz D, Martins SS, Wall MM, Hasin DS. Trends in marijuana use among pregnant and nonpregnant reproductive-aged women, 2002-2014. JAMA. 2017;317(2):207–9.

    Article  PubMed  PubMed Central  Google Scholar 

  2. McCabe JE, Arndt S. Demographic and substance abuse trends among pregnant and non-pregnant women: eleven years of treatment admission data. Matern Child Health J. 2012;16(8):1696–702.

    Article  PubMed  Google Scholar 

  3. Beatty JR, Svikis DS, Ondersma SJ. Prevalence and perceived financial costs of marijuana versus tobacco use among urban low-income pregnant women. J Addict Res Ther. 2012;3(4)

    Google Scholar 

  4. Johnston LDOMP, Bachman JG, Schulenberg JE. Monitoring the future National Results on adolescent drug use: overview of key findings, 2011. Ann Arbor: Institute for Social Research, The University of Michigan; 2012.

    Google Scholar 

  5. Hayatbakhsh MR, Flenady VJ, Gibbons KS, Kingsbury AM, Hurrion E, Mamun AA, et al. Birth outcomes associated with cannabis use before and during pregnancy. Pediatr Res. 2012;71(2):215–9.

    Article  PubMed  Google Scholar 

  6. Substance Abuse and Mental Health Services Administration (SAMHSA). Results from the 2012 national survey on drug use and health: summary of national findings, NSDUH series H-46, HHS publication no. (SMA) 13–4798. Rockville; 2013.

    Google Scholar 

  7. Ko JY, Farr SL, Tong VT, Creanga AA, Callaghan WM. Prevalence and patterns of marijuana use among pregnant and nonpregnant women of reproductive age. Am J Obstet Gynecol. 2015;213(2):201.e1–e10.

    Article  Google Scholar 

  8. Warner TD, Roussos-Ross D, Behnke M. It’s not your mother’s marijuana: effects on maternal-fetal health and the developing child. Clin Perinatol. 2014;41(4):877–94.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Volkow ND, Han B, Compton WM, Blanco C. Marijuana use during stages of pregnancy in the United States. Ann Intern Med. 2017;166(10):763–4.

    Article  PubMed  PubMed Central  Google Scholar 

  10. ElSohly MA, Mehmedic Z, Foster S, Gon C, Chandra S, Church JC. Changes in Cannabis potency over the last 2 decades (1995-2014): analysis of current data in the United States. Biol Psychiatry. 2016;79(7):613–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Calvigioni D, Hurd YL, Harkany T, Keimpema E. Neuronal substrates and functional consequences of prenatal cannabis exposure. Eur Child Adolesc Psychiatry. 2014;23(10):931–41.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Jones JTBA, Shu I. A comparison of meconium screening outcomes as an indicator of the impact of state-level relaxation of marijuana policy. Drug Alcohol Depend. 2015;156:e104–5.

    Google Scholar 

  13. Murray RM, Quigley H, Quattrone D, Englund A, Di Forti M. Traditional marijuana, high-potency cannabis and synthetic cannabinoids: increasing risk for psychosis. World Psychiatry. 2016;15(3):195–204.

    Article  PubMed  PubMed Central  Google Scholar 

  14. ElSohly M. Potency monitoring program quarterly report no.123 — reporting period: 09/16/2013–12/15/2013. Oxford: University of Mississippi, National Center for Natural Products Research; 2014.

    Google Scholar 

  15. Choi H, Heo S, Choe S, Yang W, Park Y, Kim E, et al. Simultaneous analysis of synthetic cannabinoids in the materials seized during drug trafficking using GC-MS. Anal Bioanal Chem 2013;405(12):3937–3944.

    Article  PubMed  CAS  Google Scholar 

  16. Psychoyos D, Vinod KY. Marijuana, spice ‘herbal high’, and early neural development: implications for rescheduling and legalization. Drug Test Anal. 2013;5(1):27–45.

    Article  CAS  PubMed  Google Scholar 

  17. Ustundag MF, Ozhan Ibis E, Yucel A, Ozcan H. Synthetic cannabis-induced mania. Case Rep Psychiatry. 2015;2015:310930.

    PubMed  PubMed Central  Google Scholar 

  18. Gilbert MT, Sulik KK, Fish EW, Baker LK, Dehart DB, Parnell SE. Dose-dependent teratogenicity of the synthetic cannabinoid CP-55,940 in mice. Neurotoxicol Teratol. 2016;58:15–22.

    Article  CAS  PubMed  Google Scholar 

  19. Volkow ND, Compton WM, Wargo EM. The risks of marijuana use during pregnancy. JAMA. 2017;317(2):129–30.

    Article  PubMed  Google Scholar 

  20. Roberson EK, Patrick WK, Hurwitz EL. Marijuana use and maternal experiences of severe nausea during pregnancy in Hawai’i. Hawaii J Med Public Health. 2014;73(9):283–7.

    PubMed  PubMed Central  Google Scholar 

  21. Grant KS, Petroff R, Isoherranen N, Stella N, Burbacher TM. Cannabis use during pregnancy: pharmacokinetics and effects on child development. Pharmacol Ther. 2017;

    Google Scholar 

  22. Hutchings DE, Martin BR, Gamagaris Z, Miller N, Fico T. Plasma concentrations of delta-9-tetrahydrocannabinol in dams and fetuses following acute or multiple prenatal dosing in rats. Life Sci. 1989;44(11):697–701.

    Article  CAS  PubMed  Google Scholar 

  23. Blackard C, Tennes K. Human placental transfer of cannabinoids. N Engl J Med. 1984;311(12):797.

    CAS  PubMed  Google Scholar 

  24. Fernandez-Ruiz J, Berrendero F, Hernandez ML, Ramos JA. The endogenous cannabinoid system and brain development. Trends Neurosci. 2000;23(1):14–20.

    Article  CAS  PubMed  Google Scholar 

  25. Jutras-Aswad D, DiNieri JA, Harkany T, Hurd YL. Neurobiological consequences of maternal cannabis on human fetal development and its neuropsychiatric outcome. Eur Arch Psychiatry Clin Neurosci. 2009;259(7):395–412.

    Article  PubMed  Google Scholar 

  26. Biegon A, Kerman IA. Autoradiographic study of pre- and postnatal distribution of cannabinoid receptors in human brain. NeuroImage. 2001;14(6):1463–8.

    Article  CAS  PubMed  Google Scholar 

  27. Mato S, Del Olmo E, Pazos A. Ontogenetic development of cannabinoid receptor expression and signal transduction functionality in the human brain. Eur J Neurosci. 2003;17(9):1747–54.

    Article  PubMed  Google Scholar 

  28. Wang X, Dow-Edwards D, Keller E, Hurd YL. Preferential limbic expression of the cannabinoid receptor mRNA in the human fetal brain. Neuroscience. 2003;118(3):681–94.

    Article  CAS  PubMed  Google Scholar 

  29. Friedrich J, Khatib D, Parsa K, Santopietro A, Gallicano GI. The grass isn’t always greener: the effects of cannabis on embryological development. BMC Pharmacol Toxicol. 2016;17(1):45.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  30. Berghuis P, Rajnicek AM, Morozov YM, Ross RA, Mulder J, Urban GM, et al. Hardwiring the brain: endocannabinoids shape neuronal connectivity. Science 2007;316(5828):1212–1216.

    Article  CAS  PubMed  Google Scholar 

  31. Bernard C, Milh M, Morozov YM, Ben-Ari Y, Freund TF, Gozlan H. Altering cannabinoid signaling during development disrupts neuronal activity. Proc Natl Acad Sci U S A. 2005;102(26):9388–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Watson S, Chambers D, Hobbs C, Doherty P, Graham A. The endocannabinoid receptor, CB1, is required for normal axonal growth and fasciculation. Mol Cell Neurosci. 2008;38(1):89–97.

    Article  CAS  PubMed  Google Scholar 

  33. Nagarkatti P, Pandey R, Rieder SA, Hegde VL, Nagarkatti M. Cannabinoids as novel anti-inflammatory drugs. Future Med Chem. 2009;1(7):1333–49.

    Article  CAS  PubMed  Google Scholar 

  34. Smita K, Sushil Kumar V, Premendran JS. Anandamide: an update. Fundam Clin Pharmacol. 2007;21(1):1–8.

    Article  CAS  PubMed  Google Scholar 

  35. Sido JM, Nagarkatti PS, Nagarkatti M. Role of endocannabinoid activation of peripheral CB1 receptors in the regulation of autoimmune disease. Int Rev Immunol. 2015;34(5):403–14.

    Article  CAS  PubMed  Google Scholar 

  36. Pandey R, Mousawy K, Nagarkatti M, Nagarkatti P. Endocannabinoids and immune regulation. Pharmacol Res. 2009;60(2):85–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Rieder SA, Chauhan A, Singh U, Nagarkatti M, Nagarkatti P. Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression. Immunobiology. 2010;215(8):598–605.

    Article  CAS  PubMed  Google Scholar 

  38. Paria BC, Dey SK. Ligand-receptor signaling with endocannabinoids in preimplantation embryo development and implantation. Chem Phys Lipids. 2000;108(1–2):211–20.

    Article  CAS  PubMed  Google Scholar 

  39. Correa F, Wolfson ML, Valchi P, Aisemberg J, Franchi AM. Endocannabinoid system and pregnancy. Reproduction. 2016;152(6):R191–200.

    Article  CAS  PubMed  Google Scholar 

  40. Harkany T, Keimpema E, Barabas K, Mulder J. Endocannabinoid functions controlling neuronal specification during brain development. Mol Cell Endocrinol. 2008;286(1–2 Suppl 1):S84–90.

    Article  CAS  PubMed  Google Scholar 

  41. Morris CV, DiNieri JA, Szutorisz H, Hurd YL. Molecular mechanisms of maternal cannabis and cigarette use on human neurodevelopment. Eur J Neurosci. 2011;34(10):1574–83.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Keimpema E, Mackie K, Harkany T. Molecular model of cannabis sensitivity in developing neuronal circuits. Trends Pharmacol Sci. 2011;32(9):551–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. DiNieri JA, Wang X, Szutorisz H, Spano SM, Kaur J, Casaccia P, et al. Maternal cannabis use alters ventral striatal dopamine D2 gene regulation in the offspring. Biol Psychiatry 2011;70(8):763–769.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Spano MS, Ellgren M, Wang X, Hurd YL. Prenatal cannabis exposure increases heroin seeking with allostatic changes in limbic enkephalin systems in adulthood. Biol Psychiatry. 2007;61(4):554–63.

    Article  CAS  PubMed  Google Scholar 

  45. Wu CS, Jew CP, Lu HC. Lasting impacts of prenatal cannabis exposure and the role of endogenous cannabinoids in the developing brain. Future Neurol. 2011;6(4):459–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Tortoriello G, Morris CV, Alpar A, Fuzik J, Shirran SL, Calvigioni D, et al. Miswiring the brain: Delta9-tetrahydrocannabinol disrupts cortical development by inducing an SCG10/stathmin-2 degradation pathway. EMBO J 2014;33(7):668–685.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. de Salas-Quiroga A, Diaz-Alonso J, Garcia-Rincon D, Remmers F, Vega D, Gomez-Canas M, et al. Prenatal exposure to cannabinoids evokes long-lasting functional alterations by targeting CB1 receptors on developing cortical neurons. Proc Natl Acad Sci U S A 2015;112(44):13693–13698.

    Google Scholar 

  48. Szutorisz H, DiNieri JA, Sweet E, Egervari G, Michaelides M, Carter JM, et al. Parental THC exposure leads to compulsive heroin-seeking and altered striatal synaptic plasticity in the subsequent generation. Neuropsychopharmacology 2014;39(6):1315–1323.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Olah A, Szekanecz Z, Biro T. Targeting cannabinoid signaling in the immune system: “high”-ly exciting questions, possibilities, and challenges. Front Immunol. 2017;8:1487.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  50. Zumbrun EE, Sido JM, Nagarkatti PS, Nagarkatti M. Epigenetic regulation of immunological alterations following prenatal exposure to marijuana cannabinoids and its long term consequences in offspring. J Neuroimmune Pharmacol. 2015;10(2):245–54.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Szutorisz H, Hurd YL. Epigenetic effects of Cannabis exposure. Biol Psychiatry. 2016;79(7):586–94.

    Article  CAS  PubMed  Google Scholar 

  52. Murphy LL, Gher J, Szary A. Effects of prenatal exposure to delta-9-tetrahydrocannabinol on reproductive, endocrine and immune parameters of male and female rat offspring. Endocrine. 1995;3(12):875–9.

    Article  CAS  PubMed  Google Scholar 

  53. Chasnoff IJ. Medical marijuana laws and pregnancy: implications for public health policy. Am J Obstet Gynecol. 2017;216(1):27–30.

    Article  PubMed  Google Scholar 

  54. Braillon A, Bewley S. Committee opinion no. 722: marijuana use during pregnancy and lactation. Obstet Gynecol. 2018;131(1):164.

    Article  PubMed  Google Scholar 

  55. Varner MW, Silver RM, Rowland Hogue CJ, Willinger M, Parker CB, Thorsten VR, et al. Association between stillbirth and illicit drug use and smoking during pregnancy. Obstet Gynecol 2014;123(1):113–125.

    Article  CAS  Google Scholar 

  56. Gunn JK, Rosales CB, Center KE, Nunez A, Gibson SJ, Christ C, et al. Prenatal exposure to cannabis and maternal and child health outcomes: a systematic review and meta-analysis. BMJ Open 2016;6(4):e009986.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Warshak CR, Regan J, Moore B, Magner K, Kritzer S, Van Hook J. Association between marijuana use and adverse obstetrical and neonatal outcomes. J Perinatol. 2015;35(12):991–5.

    Article  CAS  PubMed  Google Scholar 

  58. Lester BM, Tronick EZ, Brazelton TB. The neonatal intensive care unit network neurobehavioral scale procedures. Pediatrics. 2004;113(3 Pt 2):641–67.

    PubMed  Google Scholar 

  59. Fried PA. Marihuana use by pregnant women: neurobehavioral effects in neonates. Drug Alcohol Depend. 1980;6(6):415–24.

    Article  CAS  PubMed  Google Scholar 

  60. de Moraes Barros MC, Guinsburg R, de Araujo Peres C, Mitsuhiro S, Chalem E, Laranjeira RR. Exposure to marijuana during pregnancy alters neurobehavior in the early neonatal period. J Pediatr. 2006;149(6):781–7.

    Article  PubMed  CAS  Google Scholar 

  61. Dreher MC, Nugent K, Hudgins R. Prenatal marijuana exposure and neonatal outcomes in Jamaica: an ethnographic study. Pediatrics. 1994;93(2):254–60.

    CAS  PubMed  Google Scholar 

  62. Scher MS, Richardson GA, Coble PA, Day NL, Stoffer DS. The effects of prenatal alcohol and marijuana exposure: disturbances in neonatal sleep cycling and arousal. Pediatr Res. 1988;24(1):101–5.

    Article  CAS  PubMed  Google Scholar 

  63. Dahl RE, Scher MS, Williamson DE, Robles N, Day N. A longitudinal study of prenatal marijuana use. Effects on sleep and arousal at age 3 years. Arch Pediatr Adolesc Med. 1995;149(2):145–50.

    Article  CAS  PubMed  Google Scholar 

  64. Fried PA. Marihuana use by pregnant women and effects on offspring: an update. Neurobehav Toxicol Teratol. 1982;4(4):451–4.

    CAS  PubMed  Google Scholar 

  65. Huizink AC, Mulder EJ. Maternal smoking, drinking or cannabis use during pregnancy and neurobehavioral and cognitive functioning in human offspring. Neurosci Biobehav Rev. 2006;30(1):24–41.

    Article  CAS  PubMed  Google Scholar 

  66. Fried PA. Adolescents prenatally exposed to marijuana: examination of facets of complex behaviors and comparisons with the influence of in utero cigarettes. J Clin Pharmacol. 2002;42(11 Suppl):97S–102S.

    Article  CAS  PubMed  Google Scholar 

  67. Day NL, Richardson GA. Prenatal marijuana use: epidemiology, methodologic issues, and infant outcome. Clin Perinatol. 1991;18(1):77–91.

    Article  CAS  PubMed  Google Scholar 

  68. Day NL, Richardson GA, Goldschmidt L, Robles N, Taylor PM, Stoffer DS, et al. Effect of prenatal marijuana exposure on the cognitive development of offspring at age three. Neurotoxicol Teratol 1994;16(2):169–175.

    Article  CAS  PubMed  Google Scholar 

  69. Goldschmidt L, Richardson GA, Cornelius MD, Day NL. Prenatal marijuana and alcohol exposure and academic achievement at age 10. Neurotoxicol Teratol. 2004;26(4):521–32.

    Article  CAS  PubMed  Google Scholar 

  70. Hofman A, Jaddoe VW, Mackenbach JP, Moll HA, Snijders RF, Steegers EA, et al. Growth, development and health from early fetal life until young adulthood: the generation R study. Paediatr Perinat Epidemiol 2004;18(1):61–72.

    Article  PubMed  Google Scholar 

  71. El Marroun H, Tiemeier H, Steegers EA, Jaddoe VW, Hofman A, Verhulst FC, et al. Intrauterine cannabis exposure affects fetal growth trajectories: the generation R study. J Am Acad Child Adolesc Psychiatry 2009;48(12):1173–1181.

    Google Scholar 

  72. Barker DJ. In utero programming of chronic disease. Clin Sci (Lond). 1998;95(2):115–28.

    Article  CAS  Google Scholar 

  73. McLemore GL, Richardson KA. Data from three prospective longitudinal human cohorts of prenatal marijuana exposure and offspring outcomes from the fetal period through young adulthood. Data Brief 2016;9:753–757.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Volkow ND, Compton WM, Weiss SR. Adverse health effects of marijuana use. N Engl J Med. 2014;371(9):879.

    PubMed  Google Scholar 

  75. Litt MD, Kadden RM, Petry NM. Behavioral treatment for marijuana dependence: randomized trial of contingency management and self-efficacy enhancement. Addict Behav. 2013;38(3):1764–75.

    Article  PubMed  Google Scholar 

  76. Rutherford HJ, Williams SK, Moy S, Mayes LC, Johns JM. Disruption of maternal parenting circuitry by addictive process: rewiring of reward and stress systems. Front Psych. 2011;2:37.

    Google Scholar 

  77. Demont-Heinrich C BJ, editor. Marijuana use among WIC clients: a survey following legalization of recreational marijuana in Colorado. Council of State and Territorial Epidemiologists (CSTE) conference; 2015.

    Google Scholar 

  78. Bergeria CL, Heil SH. Surveying lactation professionals regarding marijuana use and breastfeeding. Breastfeed Med. 2015;10(7):377–80.

    Article  PubMed  PubMed Central  Google Scholar 

  79. American Academy of Pediatrics (AAP). American Academy of Pediatrics Reaffirms Opposition to Legalizing Marijuana for Recreational or Medical Use 2018. Available from: https://www.aap.org/en-us/about-the-aap/aap-press-room/pages/American-Academy-of-Pediatrics-Reaffirms-Opposition-to-Legalizing-Marijuana-for-Recreational-or-Medical-Use.aspx.

  80. Hale TWRH. Medications and Mother’s milk. 16th ed. Plano: Hale Publishing; 2014.

    Google Scholar 

  81. LactMed. LactMed: A ToxNet database. In: National Institutes of Health. Bethesda: US National Library of Medicine; 2015.

    Google Scholar 

  82. Jansson LM. Academy of breastfeeding medicine protocol (ABM) clinical protocol #21: guidelines for breastfeeding and the drug-dependent woman. Breastfeed Med. 2009;4(4):225–8.

    Article  PubMed  Google Scholar 

  83. Reece-Stremtan S, Marinelli KA. Academy of breastfeeding medicine (ABM) clinical protocol #21: guidelines for breastfeeding and substance use or substance use disorder, revised 2015. Breastfeed Med. 2015;10(3):135–41.

    Article  PubMed  PubMed Central  Google Scholar 

  84. Garry A, Rigourd V, Amirouche A, Fauroux V, Aubry S, Serreau R. Cannabis and breastfeeding. J Toxicol. 2009;2009:596149.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  85. Hill M, Reed K. Pregnancy, breast-feeding, and marijuana: a review article. Obstet Gynecol Surv. 2013;68(10):710–8.

    Article  PubMed  Google Scholar 

  86. Lowe RH, Abraham TT, Darwin WD, Herning R, Cadet JL, Huestis MA. Extended urinary Delta9-tetrahydrocannabinol excretion in chronic cannabis users precludes use as a biomarker of new drug exposure. Drug Alcohol Depend. 2009;105(1–2):24–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Kelly P, Jones RT. Metabolism of tetrahydrocannabinol in frequent and infrequent marijuana users. J Anal Toxicol. 1992;16(4):228–35.

    Article  CAS  PubMed  Google Scholar 

  88. Perez-Reyes M, Wall ME. Presence of delta9-tetrahydrocannabinol in human milk. N Engl J Med. 1982;307(13):819–20.

    Article  CAS  PubMed  Google Scholar 

  89. Cone EJ, Bigelow GE, Herrmann ES, Mitchell JM, LoDico C, Flegel R, et al. Nonsmoker exposure to secondhand Cannabis smoke. III. Oral fluid and blood drug concentrations and corresponding subjective effects. J Anal Toxicol 2015;39(7):497–509.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Liston J. Breastfeeding and the use of recreational drugs--alcohol, caffeine, nicotine and marijuana. Breastfeed Rev. 1998;6(2):27–30.

    CAS  PubMed  Google Scholar 

  91. Astley SJ, Little RE. Maternal marijuana use during lactation and infant development at one year. Neurotoxicol Teratol. 1990;12(2):161–8.

    Article  CAS  PubMed  Google Scholar 

  92. Tennes K, Avitable N, Blackard C, Boyles C, Hassoun B, Holmes L, et al. Marijuana: prenatal and postnatal exposure in the human. NIDA Res Monogr 1985;59:48–60.

    Google Scholar 

  93. Chang JC, Holland CL, Tarr JA, Rubio D, Rodriguez KL, Kraemer KL, et al. Perinatal Illicit Drug and Marijuana Use. Am J Health Promot 2017;31(1):35–42.

    Article  PubMed  Google Scholar 

  94. Stadterman JM, Hart CL. Screening women for marijuana use does more harm than good. Am J Obstet Gynecol. 2015;213(4):598–9.

    Article  PubMed  Google Scholar 

  95. Colorado Department of Health. Marijuana Pregnancy and Breastfeeding Guidance 2017. Available from: www.colorado.gov/pacific/sites/default/files/MJ_RMEP_Pregnancy-Breastfeeding-Clinical-Guidelines.pdf.

  96. Jarlenski M, Tarr JA, Holland CL, Farrell D, Chang JC. Pregnant Women’s access to information about perinatal marijuana use: a qualitative study. Womens Health Issues. 2016;26(4):452–9.

    Article  PubMed  PubMed Central  Google Scholar 

  97. Holland CL, Rubio D, Rodriguez KL, Kraemer KL, Day N, Arnold RM, et al. Obstetric health care Providers’ counseling responses to pregnant patient disclosures of marijuana use. Obstet Gynecol 2016;127(4):681–687.

    Article  Google Scholar 

  98. Holland CL, Nkumsah MA, Morrison P, Tarr JA, Rubio D, Rodriguez KL, et al. “Anything above marijuana takes priority”: obstetric providers’ attitudes and counseling strategies regarding perinatal marijuana use. Patient Educ Couns. 2016;99(9):1446–51.

    Article  PubMed  PubMed Central  Google Scholar 

  99. Mark K, Gryczynski J, Axenfeld E, Schwartz RP, Terplan M. Pregnant Women’s current and intended Cannabis use in relation to their views toward legalization and knowledge of potential harm. J Addict Med. 2017;11(3):211–6.

    Article  PubMed  Google Scholar 

  100. Jaques SC, Kingsbury A, Henshcke P, Chomchai C, Clews S, Falconer J, et al. Cannabis, the pregnant woman and her child: weeding out the myths. J Perinatol 2014;34(6):417–424.

    Article  CAS  PubMed  Google Scholar 

  101. Budney AJ, Roffman R, Stephens RS, Walker D. Marijuana dependence and its treatment. Addict Sci Clin Pract. 2007;4(1):4–16.

    Article  PubMed  PubMed Central  Google Scholar 

  102. Martin CE, Longinaker N, Mark K, Chisolm MS, Terplan M. Recent trends in treatment admissions for marijuana use during pregnancy. J Addict Med. 2015;9(2):99–104.

    Article  CAS  PubMed  Google Scholar 

  103. Litt MD, Kadden RM, Kabela-Cormier E, Petry NM. Coping skills training and contingency management treatments for marijuana dependence: exploring mechanisms of behavior change. Addiction. 2008;103(4):638–48.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Martha L. Velez & Lauren M. Jansson

  2. National Institute on Drug Abuse, Molecular Targets and Medications Discovery Branch, Intramural Research Program, Baltimore, MD, USA

    Chloe J. Jordan

Authors
  1. Martha L. Velez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chloe J. Jordan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lauren M. Jansson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Martha L. Velez .

Editor information

Editors and Affiliations

  1. Division of Pharma & Med Cons Drug Abuse, NIDA, NIH, Department of Health & Human Services, Bethesda, MD, USA

    Ivan D. Montoya

  2. Division of Extramural Research, National Institute on Drug Abuse Division of Extramural Research, Bethesda, MD, USA

    Susan R. B. Weiss

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Velez, M.L., Jordan, C.J., Jansson, L.M. (2019). Cannabis Use Disorder During the Perinatal Period. In: Montoya, I., Weiss, S. (eds) Cannabis Use Disorders. Springer, Cham. https://doi.org/10.1007/978-3-319-90365-1_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-90365-1_17

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-90364-4

  • Online ISBN: 978-3-319-90365-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation